Condition: HER2-positive Advanced Solid Tumor · Sponsor: DualityBio Inc.
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
This description comes directly from the study's public registry record.
Britney Winterberger · +1-513-403-8568 · britney.winterberger@tigermedgrp.com
Always discuss trial participation with your own doctor first.
| Helios Clinical Research | Cerritos, California, United States | Active Not Recruiting |
| California Research Institute | Los Angeles, California, United States | Active Not Recruiting |
| Sharp Memorial Hospital | San Diego, California, United States | Active Not Recruiting |
| Washington Cancer Institute at MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| Advanced Research LLC | Coral Springs, Florida, United States | Active Not Recruiting |
| The Oncology Institute of Hope and Innovation | Lakeland, Florida, United States | Active Not Recruiting |
| D&H Cancer Research Center LLC | Margate, Florida, United States | Active Not Recruiting |
| HCA Mercy Hospital | Miami, Florida, United States | Withdrawn |
| BRCR Medical Center Inc. | Plantation, Florida, United States | Active Not Recruiting |
| BRCR Medical Center Inc. | Tamarac, Florida, United States | Active Not Recruiting |
| Southeastern Regional Medical Center, LLC | Newnan, Georgia, United States | Active Not Recruiting |
| Kapi'olani Medical Center for Women and Children | Honolulu, Hawaii, United States | Active Not Recruiting |
+ 90 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05150691